A recent transaction between the U.S. and Canada has secured continued access to RADICAVA® for individuals with ALS. The deal, which took place on December 22, 2025, in Jersey City, New Jersey, involved Tanabe Pharma America, Inc. (TPA), a subsidiary focused on future growth and innovation. This move ensures ongoing availability of the medication for patients in need in both countries.